Home › NDC Lookup › RxCUI directory › RxCUI 242679

Abacavir 300 MG Oral Tablet — RxCUI 242679

RxNorm drug concept · Semantic clinical drug
RxCUI 242679 Semantic clinical drug · SCD ● Current RxNorm concept 11 FDA products 12 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI242679
Official nameAbacavir 300 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asabacavir (as abacavir sulfate) 300 MG Oral Tablet
FDA products mapped11
Package NDCs mapped12
Reported Medicaid activity (SDUD)1,362 prescriptions · 11 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Abacavir: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Abacavir treats HIV-1 infection. It is always taken together with other HIV medicines, never alone. Combination treatment is how it helps control the virus.
  • The HLA-B*5701 gene test shows whether you have a higher risk of a serious allergic reaction to abacavir. If you carry the gene, you should not take it. Even without the gene, reac...
  • Stop abacavir right away and contact your doctor or get emergency care. Watch for two or more of these: fever, rash, nausea, vomiting, diarrhea, belly pain, feeling very tired or a...
  • What should I do if I think I'm having an allergic reaction?
📖 Read our full Abacavir guide →

🕸️ Concept Web — How Abacavir 300 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Abacavir 300 MG Oral Tablet RxCUI 242679

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Abacavir 190521
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Ziagen 221017
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Abacavir Oral Tablet 370503
    • Abacavir Oral Product 1163063
    • Abacavir Pill 1163064
    • Abacavir Oral Tablet [Ziagen] 368253
    • Ziagen Oral Product 1187455
    • Ziagen Pill 1187456
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Abacavir 300 MG 329485
    • Abacavir 300 MG Oral Tablet [Ziagen] 213460
    • Abacavir 300 MG [Ziagen] 573348

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Abacavir 300 MG SCDC · 329485
  • Abacavir Oral Tablet SCDF · 370503
  • Abacavir Oral Product SCDG · 1163063
  • Abacavir Pill SCDG · 1163064

Brand-Name Concepts

  • Abacavir 300 MG Oral Tablet [Ziagen] SBD · 213460
  • Abacavir 300 MG [Ziagen] SBDC · 573348
  • Abacavir Oral Tablet [Ziagen] SBDF · 368253
  • Ziagen Oral Product SBDG · 1187455
  • Ziagen Pill SBDG · 1187456
  • Ziagen BN · 221017

📦 FDA Products & Package NDCs

11 products · 12 package NDCs
12 package NDCs map to RxCUI 242679 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00378-4105-91 1 BOTTLE, PLASTIC in 1 CARTON (0378-4105-91) / 60 TABLET, F... Abacavir Sulfate Mylan Pharmaceuticals Inc. 2012-06-19
00904-6874-04 30 BLISTER PACK in 1 CARTON (0904-6874-04) / 1 TABLET, FILM... Abacavir Major Pharmaceuticals 2012-12-17
00904-6874-06 50 BLISTER PACK in 1 CARTON (0904-6874-06) / 1 TABLET, FILM... Abacavir Major Pharmaceuticals 2012-12-17
31722-0557-60 60 TABLET in 1 BOTTLE (31722-557-60) Abacavir Camber Pharmaceuticals, Inc. 2021-04-01
48433-0001-06 50 BLISTER PACK in 1 CARTON (48433-001-06) / 1 TABLET, FILM... Abacavir Sulfate Safecor Health, LLC 2026-02-23
50268-0049-12 20 BLISTER PACK in 1 BOX (50268-049-12) / 1 TABLET in 1 BLI... Abacavir AvPAK 2020-04-10
51079-0204-06 50 BLISTER PACK in 1 CARTON (51079-204-06) / 1 TABLET, FILM... Abacavir Sulfate Mylan Institutional Inc. 2012-08-01
65862-0073-60 60 TABLET, FILM COATED in 1 BOTTLE (65862-073-60) Abacavir Aurobindo Pharma Limited 2012-12-17
67046-1602-03 30 TABLET in 1 BLISTER PACK (67046-1602-3) Abacavir Coupler LLC 2021-04-01
68084-0021-21 30 BLISTER PACK in 1 BOX, UNIT-DOSE (68084-021-21) / 1 TABL... Abacavir American Health Packaging 2013-02-04
69097-0514-03 60 TABLET, FILM COATED in 1 BOTTLE (69097-514-03) Abacavir Cipla USA Inc. 2017-11-21
72865-0167-60 60 TABLET in 1 BOTTLE (72865-167-60) Abacavir XLCare Pharmaceuticals Inc. 2021-05-28
Observed labelers: Major Pharmaceuticals (2) · American Health Packaging (1) · Aurobindo Pharma Limited (1) · AvPAK (1) · Camber Pharmaceuticals, Inc. (1) · Cipla USA Inc. (1) · +5 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.